Omereflux (Omeprazole)

Omereflux is a proton pump inhibitor that acts on the gastric acid secretion pathway to manage several acid‑related disorders.

• Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis.
• Peptic ulcer disease: supports ulcer healing and reduces recurrence risk.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition.
• Helicobacter pylori eradication regimens (as part of combination therapy): enhances eradication rates when used with antibiotics.
• NSAID‑induced ulcer prevention: lowers the risk of ulcer development in patients requiring long‑term NSAID therapy.

• Omeprazole inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the parietal cell surface of the stomach lining. By binding irreversibly to this pump, it blocks the final step of acid secretion, leading to a sustained increase in gastric pH and reduced acidity in the stomach.

Omereflux may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: loose stools that may resolve with continued therapy.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: cramp‑like discomfort in the stomach area.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis presenting with watery diarrhea.
• Hypomagnesemia: low serum magnesium levels that may cause muscle cramps or cardiac arrhythmia.
• Acute interstitial nephritis: kidney inflammation presenting with reduced urine output.
• Stevens‑Johnson syndrome: severe skin reaction with blistering and mucosal involvement.
• Liver enzyme elevation: increased ALT/AST indicating potential hepatic stress.
• Bone fracture risk: potential reduction in calcium absorption with long‑term use.

When prescribing Omereflux, clinicians should consider several safety aspects.

• Assess renal function: dose adjustment may be needed in severe impairment.
• Review concomitant medications: potential for drug‑drug interactions.
• Monitor for infection: prolonged acid suppression can increase risk of gastrointestinal infections.
• Evaluate bone health: long‑term therapy may affect calcium absorption.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omereflux can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk.
• Atazanavir: decreased antiviral absorption, compromising HIV therapy.
• Methotrexate (high dose): increased systemic exposure, risk of toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: possible alteration of INR, require more frequent monitoring.
• Digoxin: slight increase in serum levels, watch for toxicity signs.
• Diazepam: enhanced sedative effect, monitor patient response.